Bio-Rad Laboratories, Inc. cash flow to debt ratio of 34.76% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Bio-Rad Laboratories, Inc.'s free cash flow has increased 40.72% from $266.20M last year to $374.60M, signaling increasing performance

Bio-Rad Laboratories, Inc.'s debt to equity ratio is 0.17, which means that the company's assets are healthy financed, signaling financial stability.

Bio-Rad Laboratories, Inc.'s debt has decreased relative to shareholder equity from 0.21 last year to 0.17 today, signaling strengthened financials

Bio-Rad Laboratories, Inc. has a net cash position, so leverage is healthy.

Bio-Rad Laboratories, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Bio-Rad Laboratories, Inc.'s profit margin has increased (-111.95%) in the last year from -71.86% to 8.59%, signaling increasing performance

Bio-Rad Laboratories, Inc.'s short-term assets of $2.91B exceed its short-term liabilities of $517.00M

Bio-Rad Laboratories, Inc.'s return on assets of 2.17% is lower than the 5.00% threshold, indicating inefficient asset utilization

Bio-Rad Laboratories, Inc.'s return on equity of 3.15%, is lower than 15.00%, indicating bad performance

Bio-Rad Laboratories, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Bio-Rad Laboratories, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Bio-Rad Laboratories, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Bio-Rad Laboratories, Inc. has a free cash flow yield of 3.93%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Bio-Rad Laboratories, Inc.'s yearly earnings has increased -141.20% since last year from $-1.84B to $759.90M, signaling increasing performance

Bio-Rad Laboratories, Inc.'s yearly revenue has increased 0.65% since last year from $2.57B to $2.58B, signaling increasing performance

ROIC 1.54% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Bio-Rad Laboratories, Inc.'s 3-year revenue CAGR of -2.68% is negative, indicating declining revenue over the past 3 years

Bio-Rad Laboratories, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Bio-Rad Laboratories, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Bio-Rad Laboratories, Inc. is overvalued relative to its fair value price of 95.45 based on Discounted Cash Flow model

Bio-Rad Laboratories, Inc. has an earnings yield of 2.35%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Bio-Rad Laboratories, Inc. is overvalued relative to its fair value price of 86.41 based on EBITDA multiple model

Bio-Rad Laboratories, Inc. has an EV/EBITDA ratio of 7.63x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Bio-Rad Laboratories, Inc. is overvalued relative to its fair value price of 177.34 based on Earnings Fair Value model

Bio-Rad Laboratories, Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Bio-Rad Laboratories, Inc. has a price-to-book ratio of 1.32x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Bio-Rad Laboratories, Inc. has a price-to-sales ratio of 3.66x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue